(AIM-HI Accelerator Fund) A portfolio start-up company of the AIM-HI Accelerator Fund has been awarded $700,000 from Virginia Catalyst to commercialize its lead cancer drug candidate. InterLeukin Combinatorial Therapies is a firm spun out of the laboratory of Virginia Commonwealth University’s Paul Fisher, M.Ph., Ph.D., with an initial $750,000 investment from AIM-HI.

Original source: https://www.eurekalert.org/pub_releases/2019-12/aaf-aaf122319.php